“…In ALS and FTLD pathology, not only full-length TDP-43 but also TDP-43 CTFs are included in the condensates in the brain, but are rarely detected in the spinal cord (Neumann et al , 2006; Smethurst et al , 2016). Therefore, it has been proposed that TDP-43 CTFs may not be a prerequisite for neurodegeneration (Berning & Walker, 2019; Lee et al , 2011); however, TDP-43 fragmentation and its CTFs are a potential therapeutic target because ectopic expression of TDP-43 CTFs leads to various dysfunctions such as impaired autophagy and proteasome function, reducing functional dimerization/oligomerization of TDP-43, reduced motor function, and cell death, in cellular models and also in animal models (Caccamo et al , 2015; Chhangani et al , 2021; Fazal et al , 2021; Kitamura et al , 2016; Wang et al , 2015). Consequently, the proteotoxic mechanism of TDP-43 CTFs remains elusive.…”